

Patrick Neven

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3082281/publications.pdf>

Version: 2024-02-01

183
papers

13,403
citations

53751

45
h-index

26591

107
g-index

187
all docs

187
docs citations

187
times ranked

17375
citing authors

#	ARTICLE	IF	CITATIONS
1	Cognitions and physical impairments in relation to upper limb function in women with pain and myofascial dysfunctions in the late stage after breast cancer surgery: an exploratory cross-sectional study. <i>Disability and Rehabilitation</i> , 2022, 44, 5212-5219.	0.9	2
2	Comparing breast cancer imaging characteristics of CHEK2 with BRCA1 and BRCA2 gene mutation carriers. <i>European Journal of Radiology</i> , 2022, 146, 110074.	1.2	4
3	Preventing taxane-related peripheral neuropathy, pain and nail toxicity: a prospective self-controlled trial comparing hilotherapy with frozen gloves in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 293-301.	1.1	7
4	Clinical Significance of <i>PIK3CA</i> and <i>ESR1</i> Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant. <i>Clinical Cancer Research</i> , 2022, 28, 1500-1506.	3.2	35
5	Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. <i>European Journal of Cancer</i> , 2022, 164, 39-51.	1.3	8
6	Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer. <i>Gynecologic Oncology</i> , 2022, 165, 14-22.	0.6	14
7	Validation of a prognostic scoring system for postmastectomy locoregional recurrence in breast cancer. <i>Breast</i> , 2022, 64, 29-34.	0.9	1
8	Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer. <i>Npj Genomic Medicine</i> , 2022, 7, 30.	1.7	4
9	Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer. <i>Annals of Oncology</i> , 2022, 33, 769-785.	0.6	37
10	Pan-Cancer Detection and Typing by Mining Patterns in Large Genome-Wide Cell-Free DNA Sequencing Datasets. <i>Clinical Chemistry</i> , 2022, 68, 1164-1176.	1.5	6
11	Body Mass Index and Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 146-153.	3.0	31
12	Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 697-707.	1.1	8
13	Ribociclib plus fulvestrant in the treatment of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 93-106.	1.1	9
14	Scalp cooling in breast cancer patients treated with docetaxel+cyclophosphamide: patient- and nurse-reported results. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 715-722.	1.1	4
15	A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 8.	2.2	15
16	Concordance between results of inexpensive statistical models and multigene signatures in patients with ER+/HER2 ⁻ early breast cancer. <i>Modern Pathology</i> , 2021, 34, 1297-1309.	2.9	5
17	The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 155-165.	1.1	18
18	The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers. <i>Scientific Reports</i> , 2021, 11, 3176.	1.6	17

#	ARTICLE	IF	CITATIONS
19	Postpartum breast cancer: mechanisms underlying its worse prognosis, treatment implications, and fertility preservation. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 412-422.	1.2	14
20	Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls.. <i>Journal of Clinical Oncology</i> , 2021, 39, 515-515.	0.8	1
21	A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. <i>Nature Medicine</i> , 2021, 27, 820-832.	15.2	330
22	Comprehensive genome-wide analysis of routine non-invasive test data allows cancer prediction: A single-center retrospective analysis of over 85,000 pregnancies. <i>EClinicalMedicine</i> , 2021, 35, 100856.	3.2	42
23	Blood Immunosenescence Signatures Reflecting Age, Frailty and Tumor Immune Infiltrate in Patients with Early Luminal Breast Cancer. <i>Cancers</i> , 2021, 13, 2185.	1.7	2
24	Cause of death for patients with breast cancer: discordance between death certificates and medical files, and impact on survival estimates. <i>Archives of Public Health</i> , 2021, 79, 111.	1.0	5
25	Toward predicting CYP2D6-mediated variable drug response from <i>CYP2D6</i> gene sequencing data. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	42
26	Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial. <i>Breast Cancer Research</i> , 2021, 23, 87.	2.2	21
27	Sacituzumab govitecan and trastuzumab deruxtecan: two new antibodyâ€“drug conjugates in the breast cancer treatment landscape. <i>ESMO Open</i> , 2021, 6, 100204.	2.0	30
28	Detection of secondary metastatic breast cancer by measurement of plasma CA 15.3. <i>ESMO Open</i> , 2021, 6, 100203.	2.0	8
29	Breast cancer diagnosed in the post-weaning period is indicative for a poor outcome. <i>European Journal of Cancer</i> , 2021, 155, 13-24.	1.3	7
30	Radical hysterectomy without adjuvant radiotherapy in patients with cervix carcinoma FIGO 2009 IB1, with or without positive Sedlis criteria. <i>Gynecologic Oncology</i> , 2021, 162, 539-545.	0.6	7
31	FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 125.	2.3	9
32	Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy. <i>Annals of Oncology</i> , 2021, 32, 1256-1266.	0.6	16
33	Data describing the poor outcome associated with a breast cancer diagnosis in the post-weaning period. <i>Data in Brief</i> , 2021, 38, 107354.	0.5	2
34	Features of durable response and treatment efficacy for capecitabine monotherapy in advanced breast cancer: real-world evidence from a large single-centre cohort. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1041-1048.	1.2	1
35	Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 183-194.	1.1	14
36	Risk-reducing mastectomy in BRCA carriers: survival is not the issue. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 251-252.	1.1	5

#	ARTICLE	IF	CITATIONS
37	The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2. <i>JAMA Oncology</i> , 2020, 6, 116.	3.4	572
38	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	9.4	120
39	Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 514-524.	13.9	482
40	Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature. <i>Cancers</i> , 2020, 12, 3317.	1.7	19
41	Breast Cancer Detection and Treatment Monitoring Using a Noninvasive Prenatal Testing Platform: Utility in Pregnant and Nonpregnant Populations. <i>Clinical Chemistry</i> , 2020, 66, 1414-1423.	1.5	9
42	Assessment of stromal tumor infiltrating lymphocytes and immunohistochemical features in invasive micropapillary breast carcinoma with long-term outcomes. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 985-998.	1.1	9
43	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020, 52, 572-581.	9.4	265
44	Exposure-response analysis of endoxifen serum concentrations in early-breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 1141-1152.	1.1	10
45	Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in <i>BRCA1/2</i> : A Review of Secondary Prevention Guidelines. <i>Journal of Oncology</i> , 2020, 2020, 1-13.	0.6	20
46	Uterine ultrasound and endometrial biopsy in tamoxifen users. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 833-834.	1.1	6
47	Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population. <i>Clinical and Translational Oncology</i> , 2020, 22, 1857-1866.	1.2	2
48	Effects of a mindfulness-based intervention on cancer-related cognitive impairment: Results of a randomized controlled functional magnetic resonance imaging pilot study. <i>Cancer</i> , 2020, 126, 4246-4255.	2.0	32
49	Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 661-670.	2.3	17
50	Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D. <i>Gynecologic Oncology</i> , 2020, 157, 245-251.	0.6	24
51	A Systematic Review of Estimating Breast Cancer Recurrence at the Population Level With Administrative Data. <i>Journal of the National Cancer Institute</i> , 2020, 112, 979-988.	3.0	17
52	Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen. <i>Frontiers in Pharmacology</i> , 2020, 11, 283.	1.6	19
53	Inflammatory breast cancer cells are characterized by abrogated TGF β 1-dependent cell motility and SMAD3 activity. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 385-395.	1.1	18
54	Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results. <i>Journal of Clinical Oncology</i> , 2020, 38, 1006-1006.	0.8	52

#	ARTICLE	IF	CITATIONS
55	Sequential intra-arterial infusion of 90Y-resin microspheres and mitomycin C in chemo refractory liver metastatic breast cancer patients: a single centre pilot study. <i>Radiology and Oncology</i> , 2020, 54, 33-39.	0.6	5
56	The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars. <i>British Journal of Cancer</i> , 2019, 121, 199-210.	2.9	48
57	Age-dependent brain volume and neuropsychological changes after chemotherapy in breast cancer patients. <i>Human Brain Mapping</i> , 2019, 40, 4994-5010.	1.9	25
58	Two truncating variants in FANCC and breast cancer risk. <i>Scientific Reports</i> , 2019, 9, 12524.	1.6	5
59	Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and Blueprint® Kit at University Hospitals Leuven and Curie Institute Paris. <i>Translational Oncology</i> , 2019, 12, 1557-1565.	1.7	6
60	Reply to C.L. Braal et al, H. Brauch et al, and M.P. Goetz et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 1984-1985.	0.8	2
61	Intra-arterial Mitomycin C infusion in a large cohort of advanced liver metastatic breast cancer patients: safety, efficacy and factors influencing survival. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 597-605.	1.1	7
62	Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 699-708.	1.1	22
63	Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer. <i>Neoplasia</i> , 2019, 21, 582-590.	2.3	24
64	Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 636-646.	0.8	72
65	EP877 Intestinal (sub)obstruction in ovarian cancer patients: management, complications and survival. , 2019, , .		0
66	Myeloid-derived suppressor cells at diagnosis may discriminate between benign and malignant ovarian tumors. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1381-1388.	1.2	17
67	Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer. <i>Oncologist</i> , 2019, 24, 165-171.	1.9	23
68	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. <i>American Journal of Human Genetics</i> , 2019, 104, 21-34.	2.6	711
69	Stromal characteristics are adequate prognosticators for recurrence risk in ductal carcinoma in situ of the breast. <i>European Journal of Surgical Oncology</i> , 2019, 45, 550-559.	0.5	14
70	Identification, clinical-pathological characteristics and treatment outcomes of patients with metastatic breast cancer and somatic human epidermal growth factor receptor 2 (ERBB2) mutations. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 55-63.	1.1	3
71	Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5507-5507.	0.8	36
72	Juvenile Papillomatosis: A Case Report. <i>The Journal of Breast Health</i> , 2019, 15, 130-134.	0.4	5

#	ARTICLE	IF	CITATIONS
73	Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial. <i>Clinical Cancer Research</i> , 2018, 24, 2312-2318.	3.2	51
74	Effectiveness of Botulinum Toxin A for Persistent Upper Limb Pain After Breast Cancer Treatment: A Double-Blinded Randomized Controlled Trial. <i>Archives of Physical Medicine and Rehabilitation</i> , 2018, 99, 1342-1351.	0.5	14
75	Breast cancer subtype and survival by parity and time since last birth. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 481-487.	1.1	6
76	Low levels of intra-tumoural T cells in breast cancer identify clinically frail patients with shorter disease-specific survival. <i>Journal of Geriatric Oncology</i> , 2018, 9, 606-612.	0.5	5
77	Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab. <i>Acta Clinica Belgica</i> , 2018, 73, 100-109.	0.5	42
78	Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors. <i>Supportive Care in Cancer</i> , 2018, 26, 869-878.	1.0	39
79	Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 551-557.	1.1	33
80	Body mass index, age at breast cancer diagnosis, and breast cancer subtype: a cross-sectional study. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 189-196.	1.1	7
81	Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. <i>Journal of Clinical Oncology</i> , 2018, 36, 2465-2472.	0.8	704
82	Ribociclib (RIB) + fulvestrant (FUL) in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-negative) advanced breast cancer (ABC): MONALEESA-3 biomarker analyses. <i>Annals of Oncology</i> , 2018, 29, viii113-viii114.	0.6	2
83	Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer. <i>Clinical Drug Investigation</i> , 2018, 38, 1071-1075.	1.1	4
84	Early drain removal improves quality of life and clinical outcomes in patients with breast cancer - Results from a randomised controlled trial. <i>European Journal of Oncology Nursing</i> , 2018, 36, 112-118.	0.9	10
85	Manual lymph drainage may not have a preventive effect on the development of breast cancer-related lymphoedema in the long term: a randomised trial. <i>Journal of Physiotherapy</i> , 2018, 64, 245-254.	0.7	25
86	The genetic landscape of 87 ovarian germ cell tumors. <i>Gynecologic Oncology</i> , 2018, 151, 61-68.	0.6	44
87	Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 131-141.	1.1	12
88	Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 1199.	3.4	139
89	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. <i>Nature Genetics</i> , 2018, 50, 968-978.	9.4	184
90	Immune profiles of elderly breast cancer patients are altered by chemotherapy and relate to clinical frailty. <i>Breast Cancer Research</i> , 2017, 19, 20.	2.2	32

#	ARTICLE	IF	CITATIONS
91	The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2 ⁻) breast cancer: When might multigene assays be of value?. <i>Breast</i> , 2017, 33, 191-199.	0.9	4
92	Pain characteristics as important contributing factors to upper limb dysfunctions in breast cancer survivors at long term. <i>Musculoskeletal Science and Practice</i> , 2017, 29, 52-59.	0.6	36
93	Advances in the treatment of advanced oestrogen-receptor-positive breast cancer. <i>Lancet, The</i> , 2017, 389, 2403-2414.	6.3	168
94	Association analysis identifies 65 new breast cancer risk loci. <i>Nature</i> , 2017, 551, 92-94.	13.7	1,099
95	Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses. <i>Clinical Cancer Research</i> , 2017, 23, 2223-2231.	3.2	80
96	Inter-rater reliability of shoulder measurements in middle-aged women. <i>Physiotherapy</i> , 2017, 103, 222-230.	0.2	24
97	Body mass index and breast cancer survival: a Mendelian randomization analysis. <i>International Journal of Epidemiology</i> , 2017, 46, 1814-1822.	0.9	45
98	Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study. <i>Breast Cancer Research</i> , 2017, 19, 119.	2.2	43
99	MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2 ⁻ Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 2875-2884.	0.8	1,105
100	Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. <i>Oncotarget</i> , 2016, 7, 80140-80163.	0.8	31
101	Safety of everolimus plus exemestane in patients with hormone-receptor ⁺ positive, HER2 ⁻ negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET). <i>Annals of Oncology</i> , 2016, 27, 1719-1725.	0.6	64
102	Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. <i>Cancer Causes and Control</i> , 2016, 27, 679-693.	0.8	21
103	Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1503-1510.	1.1	64
104	Arm lymphoedema and upper limb impairments in sentinel node-negative breast cancer patients: A one year follow-up study. <i>Breast</i> , 2016, 29, 102-108.	0.9	48
105	Combined modality adjuvant therapy for high-risk endometrial cancer. <i>Lancet Oncology, The</i> , 2016, 17, 1029-1030.	5.1	6
106	Extending the Developmental Origins of Health and Disease theory: does paternal diet contribute to breast cancer risk in daughters?. <i>Breast Cancer Research</i> , 2016, 18, 103.	2.2	11
107	The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients. <i>British Journal of Cancer</i> , 2016, 115, 1471-1478.	2.9	45
108	Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. <i>Lancet, The</i> , 2016, 387, 866-873.	6.3	149

#	ARTICLE	IF	CITATIONS
109	Androgen deprivation by adrenal suppression using low-dose hydrocortisone for the treatment of breast carcinoma with apocrine features: a case report illustrating this new paradigm. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 603-607.	1.1	6
110	Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients. <i>European Journal of Cancer</i> , 2016, 56, 31-36.	1.3	23
111	Evaluation of a breast cancer nomogram to predict ipsilateral breast relapse after breast-conserving therapy. <i>Radiotherapy and Oncology</i> , 2016, 119, 45-51.	0.3	7
112	Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer. <i>Annals of Oncology</i> , 2016, 27, 106-113.	0.6	58
113	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016, 141, 386-401.	0.6	18
114	The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters. <i>Oncotarget</i> , 2016, 7, 29977-29988.	0.8	39
115	Does patient education work in breast cancer? Final results from the global CARIATIDE study. <i>Future Oncology</i> , 2015, 11, 205-217.	1.1	23
116	Prognostic features of breast cancer differ between women in the Democratic Republic of Congo and Belgium. <i>Breast</i> , 2015, 24, 642-648.	0.9	16
117	A new era of improving progression-free survival with dual blockade in postmenopausal HR+, HER2 ⁺ advanced breast cancer. <i>Cancer Treatment Reviews</i> , 2015, 41, 94-104.	3.4	22
118	Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. <i>Carcinogenesis</i> , 2015, 36, 256-271.	1.3	14
119	Effectiveness of Postoperative Physical Therapy for Upper-Limb Impairments After Breast Cancer Treatment: A Systematic Review. <i>Archives of Physical Medicine and Rehabilitation</i> , 2015, 96, 1140-1153.	0.5	159
120	Safety of aromatase inhibitor therapy in breast cancer. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1201-1211.	1.0	23
121	Neoadjuvant chemotherapy followed by large cone resection as fertility-sparing therapy in stage IB cervical cancer. <i>Gynecologic Oncology</i> , 2015, 139, 447-451.	0.6	45
122	Withdrawal of hormone replacement therapy might affect multigene signature results in early luminal breast cancer. <i>Annals of Oncology</i> , 2015, 26, 437-438.	0.6	3
123	Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer. <i>BMC Pharmacology & Toxicology</i> , 2015, 16, 2.	1.0	33
124	Quality of pathology reporting is crucial for cancer care and registration: A baseline assessment for breast cancers diagnosed in Belgium in 2008. <i>Breast</i> , 2015, 24, 143-152.	0.9	8
125	CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 373-384.	1.1	26
126	CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 583-590.	1.1	54

#	ARTICLE	IF	CITATIONS
127	Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. <i>Nature Genetics</i> , 2015, 47, 1294-1303.	9.4	357
128	Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 67-76.	1.1	61
129	ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 543-555.	1.1	16
130	The UZ Leuven Policy for Extended Adjuvant Anti-estrogen Therapy in Women With Early Estrogen Receptor-Positive Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2015, 16, 31.	1.3	0
131	Biological ageing and frailty markers in breast cancer patients. <i>Aging</i> , 2015, 7, 319-333.	1.4	45
132	A Core Invasiveness Gene Signature Reflects Epithelial-to-Mesenchymal Transition but Not Metastatic Potential in Breast Cancer Cell Lines and Tissue Samples. <i>PLoS ONE</i> , 2014, 9, e89262.	1.1	13
133	Fracture incidence after 3 years of aromatase inhibitor therapy™. <i>Annals of Oncology</i> , 2014, 25, 1665-1666.	0.6	0
134	The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: First-year results from the Compliance of Aromatase Inhibitors Assessment In Daily practice through Educational approach (CARIATIDE) study. <i>Breast</i> , 2014, 23, 393-399.	0.9	44
135	Prediction of non-sentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. <i>Breast</i> , 2014, 23, 453-459.	0.9	15
136	Adverse events with everolimus in BOLERO-2. <i>Annals of Oncology</i> , 2014, 25, 1861.	0.6	1
137	Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 557-570.	1.1	23
138	Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens. <i>European Journal of Cancer</i> , 2014, 50, 2925-2931.	1.3	14
139	Aromatase inhibitors in the breast cancer clinic: focus on exemestane. <i>Endocrine-Related Cancer</i> , 2014, 21, R31-R49.	1.6	59
140	Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. <i>Nature</i> , 2014, 514, 92-97.	13.7	548
141	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. <i>Nature Communications</i> , 2014, 5, 4999.	5.8	105
142	Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. <i>Annals of Oncology</i> , 2014, 25, 2357-2362.	0.6	446
143	A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 109-116.	1.1	32
144	Prognostic implications of lobular breast cancer histology: New insights from a single hospital cross-sectional study and SEER data. <i>Breast</i> , 2014, 23, 371-377.	0.9	10

#	ARTICLE	IF	CITATIONS
145	Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors. <i>BMC Cancer</i> , 2014, 14, 201.	1.1	20
146	Sexual functioning in women after mastectomy versus breast conserving therapy for early-stage breast cancer: A prospective controlled study. <i>Breast</i> , 2014, 23, 629-636.	0.9	116
147	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. <i>Breast Cancer Research</i> , 2014, 16, R51.	2.2	14
148	CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 216-227.	2.3	150
149	Sensitive routine liquid chromatography-tandem mass spectrometry method for serum estradiol and estrone without derivatization. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 8569-8577.	1.9	54
150	Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC). <i>Annals of Oncology</i> , 2013, 24, 1513-1525.	0.6	57
151	The "Leuven" paclitaxel/carboplatin weekly regimen in patients with recurrent ovarian cancer, a retrospective study. <i>Gynecologic Oncology</i> , 2013, 128, 34-37.	0.6	9
152	Tamoxifen therapy for patients with breast cancer. <i>Lancet</i> , The, 2013, 381, 2078.	6.3	2
153	Genome-wide association studies identify four ER negative-specific breast cancer risk loci. <i>Nature Genetics</i> , 2013, 45, 392-398.	9.4	374
154	Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data. <i>Annals of Oncology</i> , 2013, 24, 350-355.	0.6	35
155	Breast cancer phenotype, nodal status and palpability may be useful in the detection of overdiagnosed screening-detected breast cancers. <i>Annals of Oncology</i> , 2013, 24, 1847-1852.	0.6	34
156	Health-related quality of life and disease symptoms in postmenopausal women with HR ⁺ , HER2 ⁻ advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy. <i>Current Medical Research and Opinion</i> , 2013, 29, 1463-1473.	0.9	24
157	Need for Estradiol Assays With a Lower Functional Sensitivity in Clinical Studies Examining Postmenopausal Women Treated With Aromatase Inhibitors. <i>Journal of Clinical Oncology</i> , 2013, 31, 509-509.	0.8	10
158	Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers. <i>Annals of Oncology</i> , 2012, 23, 2578-2584.	0.6	46
159	Managing the side effects of oral aromatase inhibitors. <i>Breast Cancer Management</i> , 2012, 1, 165-173.	0.2	0
160	CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial. <i>Journal of the National Cancer Institute</i> , 2012, 104, 441-451.	3.0	316
161	Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies. <i>Journal of the National Cancer Institute</i> , 2011, 103, 250-263.	3.0	596
162	Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. <i>Lancet Oncology</i> , The, 2011, 12, 1101-1108.	5.1	356

#	ARTICLE	IF	CITATIONS
163	Lobular and non-lobular breast cancers differ regarding axillary lymph node metastasis: a cross-sectional study on 4,292 consecutive patients. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 429-435.	1.1	26
164	Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis. <i>Annals of Oncology</i> , 2011, 22, 1763-1769.	0.6	37
165	Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor-Positive Metastatic Breast Cancer: A Randomized Phase II Study. <i>Clinical Cancer Research</i> , 2011, 17, 1147-1159.	3.2	158
166	Postpartum breast cancer behaves differently. <i>Facts, Views & Vision in ObGyn</i> , 2011, 3, 183-8.	0.5	4
167	Qualitative Assessment of the Progesterone Receptor and HER2 Improves the Nottingham Prognostic Index Up to 5 Years After Breast Cancer Diagnosis. <i>Journal of Clinical Oncology</i> , 2010, 28, 4129-4134.	0.8	51
168	Activity of fulvestrant in HER2-overexpressing advanced breast cancer. <i>Annals of Oncology</i> , 2010, 21, 1246-1253.	0.6	20
169	Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 349-358.	1.1	18
170	Fulvestrant (Faslodex [®]) in advanced breast cancer: clinical experience from a Belgian cooperative study. <i>Breast Cancer Research and Treatment</i> , 2008, 109, 59-65.	1.1	19
171	Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 110, 153-159.	1.1	11
172	A pilot study to investigate the feasibility and cardiac effects of pegylated liposomal doxorubicin (PL-DOX) as adjuvant therapy in medically fit elderly breast cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 67, 133-138.	2.0	17
173	OC001: Prospective assessment of simple rules to distinguish between malignant and benign adnexal masses prior to surgery. <i>Ultrasound in Obstetrics and Gynecology</i> , 2008, 32, 243-243.	0.9	0
174	Does Estrogen Receptor-Negative/Progesterone Receptor-Positive Breast Carcinoma Exist?. <i>Journal of Clinical Oncology</i> , 2008, 26, 335-336.	0.8	91
175	Prospective Study to Assess Short-Term Intra-Articular and Tenosynovial Changes in the Aromatase Inhibitor-Associated Arthralgia Syndrome. <i>Journal of Clinical Oncology</i> , 2008, 26, 3147-3152.	0.8	130
176	Tamoxifen or Aromatase Inhibitors in Breast Cancer: Efficacy and Safety. <i>Acta Chirurgica Belgica</i> , 2007, 107, 240-256.	0.2	2
177	Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age. <i>Breast Cancer Research and Treatment</i> , 2007, 106, 127-133.	1.1	19
178	Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related. <i>Breast Cancer Research and Treatment</i> , 2005, 91, 81-87.	1.1	56
179	New SERMs in development. <i>European Journal of Cancer</i> , 2002, 38, 26-27.	1.3	4
180	The origin of postmenopausal oestrogens. <i>European Journal of Cancer</i> , 2002, 38, 29-30.	1.3	6

#	ARTICLE	IF	CITATIONS
181	Should tamoxifen users be screened for endometrial lesions?. Lancet, The, 1998, 351, 155-157.	6.3	48
182	Genomic changes in endometrial polyps associated with tamoxifen show no evidence for its action as an external carcinogen. Cancer Research, 1998, 58, 2278-81.	0.4	23
183	TAMOXIFEN AND THE UTERUS AND ENDOMETRIUM. Lancet, The, 1989, 333, 375-376.	6.3	175